28 completed, 16 active not recruiting, 6 recruiting, 3 terminated. 57 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 57 | Completed 28, Active not recruiting 16, Recruiting 6, Terminated 3, Unknown 3, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow Revlimid: new trials by email Literature Review of Revlimid trials Research Report on Revlimid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-01 | 2026-07-15 |
| Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma Dexrazoxane, Rituximab, Cyclophosphamide - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 324 | 2024-08-15 | 2026-09-23 |
| A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma Odronextamab, Lenalidomide, Rituximab - Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 580 | 2023-12-28 | 2026-10-07 |
| A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation idecabtagene vicleucel, Lenalidomide, Fludarabine - Multiple Myeloma | Phase 3 | Active not recruiting | Celgene | 79 | 2023-10-16 | 2026-03-05 |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Plasma Cell Myeloma | Phase 3 | Recruiting | SWOG Cancer Research Network | 510 | 2023-10-12 | 2026-06-10 |
| CURATE.AI Optimized Modulation for Multiple Myeloma Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma | Phase 2 / Phase 3 | Unknown | National University Hospital, Singapore | 20 | 2023-09-10 | 2023-09-06 |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma Zanubrutinib, Rituximab, Lenalidomide - Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Active not recruiting | BeOne Medicines | 799 | 2022-03-10 | 2026-10-15 |
| Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Multiple Myeloma | Phase 3 | Completed | National Cancer Institute (NCI) | 1 | 2022-02-16 | 2025-05-23 |
| MInimal Residual Disease Adapted Strategy Isatuximab, ASCT - Multiple Myeloma | Phase 3 | Active not recruiting | Intergroupe Francophone du Myelome | 791 | 2021-12-08 | 2024-11-07 |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 1450 | 2021-02-24 | 2026-08-19 |
| Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance - Multiple Myeloma | Phase 3 | Unknown | University of Leeds | 740 | 2020-08-04 | 2021-06-15 |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma Daratumumab, Dexamethasone, Lenalidomide - Smoldering Plasma Cell Myeloma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 288 | 2019-09-16 | 2026-08-19 |
| S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration Lenalidomide, Daratumumab/rHuPH20 - Multiple Myeloma | Phase 3 | Active not recruiting | SWOG Cancer Research Network | 1100 | 2019-08-13 | 2026-09-17 |
| A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant Carfilzomib, Lenalidomide, Dexamethasone - Multiple Myeloma, New Diagnosis Tumor | Phase 3 | Active not recruiting | Fondazione EMN Italy Onlus | 84 | 2019-07-01 | 2026-09-21 |
| Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) Carfilzomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Active not recruiting | University of Chicago | 250 | 2019-05-07 | 2026-03-04 |
| A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 3 | Completed | Janssen Research & Development, LLC | 395 | 2018-11-06 | 2026-11-03 |
| Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) Lenalidomide, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 3 | Active not recruiting | University of Heidelberg Medical Center | 662 | 2018-10-18 | 2026-02-03 |
| Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma Lenalidomide, Dexamethasone, No further treatment - Plasmacytoma | Phase 3 | Active not recruiting | University College, London | 36 | 2017-03-10 | 2022-12-23 |
| Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma Lenalidomide, Carfilzomib, Dexamethasone - Multiple Myeloma | Phase 3 | Active not recruiting | University of Chicago | 180 | 2016-04-26 | 2026-03-04 |
| BiRd vs. Rd as Initial Therapy in Multiple Myeloma Clarithromycin, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Weill Medical College of Cornell University | 12 | 2016-02-01 | 2023-06-05 |
Showing 20 of 57. Sign in to see all of them.
Multiple Myeloma (32) · Lymphoma, Follicular (4) · Anemia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Mantle-Cell (3) · Myelodysplastic Syndromes (3) · Recurrence (3) · Smoldering Multiple Myeloma (3) · Lymphoma, B-Cell, Marginal Zone (2) · Neoplasms, Plasma Cell (2) · Back Pain (1) · Blood Protein Disorders (1) · Cardiotoxicity (1) · Dendritic Cell Sarcoma, Interdigitating (1)
Celgene (13) · National Cancer Institute (NCI) (7) · Celgene Corporation (5) · The Lymphoma Academic Research Organisation (4) · ECOG-ACRIN Cancer Research Group (3) · Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH (2) · SWOG Cancer Research Network (2) · University of Chicago (2) · University of Heidelberg Medical Center (2) · University of Leeds (2) · Amgen (1) · BeOne Medicines (1) · Dr. med. Lars-Olof Muegge (1) · Fondazione EMN Italy Onlus (1) · Fondazione Italiana Linfomi - ETS (1)
United States (31) · Germany (21) · France (20) · Belgium (18) · Spain (18) · United Kingdom (18) · Italy (16) · Israel (15) · Poland (15) · Australia (13) · Austria (13) · Canada (13) · Czechia (10) · Portugal (10) · Netherlands (9)
Robert Knight, MD (5) · Franck Morschhauser, MD, PhD (2) · Hartmut Goldschmidt, Prof. Dr. (2) · Shaji K Kumar (2) · A. van Rhenen, MD (1) · Albert Hoenekopp, MD (1) · Alexander K Stewart (1) · Amit K Verma (1) · Amrita Krishnan, MD, FACP (1) · Andrzej Jakubowiak, MD (1) · Andrzej Jakubowiak, MD, PhD (1) · Anna Fink, MD (1) · Annamaria Brioli, MD (1) · Antonio Palumbo, M.D. (1)
PMID 18799726, PMID 19901114, PMID 21273172, PMID 37990162, PMID 39374535, PMID 41915772, PMID 18032762, PMID 18032763, PMID 19332768, PMID 19853510, PMID 21109690, PMID 21753188, PMID 21860025, PMID 22292853, PMID 22571200, PMID 22571201, PMID 22571202, PMID 22689675, PMID 23242595, PMID 23422747, PMID 23834234, PMID 24682512, PMID 25482145, PMID 25743937, PMID 25840600, PMID 26157076, PMID 27354480, PMID 27550953, PMID 27560549, PMID 28017406, PMID 28106903, PMID 28140392, PMID 28373701, PMID 28586789, PMID 28651604, PMID 28826616, PMID 28916311, PMID 28958469, PMID 29322849, PMID 29472356, PMID 30184451, PMID 31138244, PMID 31537689, PMID 31633999, PMID 31652094, PMID 31978225, PMID 32064987, PMID 32673385, PMID 32866432, PMID 33278600
U10CA180820 (8), U10CA021115 (5), U10CA180888 (3), U24CA196172 (3), 2005 (2), 2023 (2), 2004 (1), 2008 (1), 2009 (1), 2015 (1), 2018 (1), U10CA031946 (1), U10CA032102 (1), U10CA180821 (1)